Diffuse large B cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma
worldwide, representing approximately 30–40% of all cases in different geographic regions …

Diffuse large B-cell lymphoma (DLBCL) is a clinically heterogeneous lymphoid malignancy
and the most common subtype of non-Hodgkin's lymphoma in adults, with one of the highest …

Purpose To determine whether any tumor biomarkers could account for the survival
advantage observed in the LNH 03-2B trial among patients with diffuse large B-cell …

Background Several biomarkers indicating poor prognosis have been reassessed in
patients receiving rituximab combination chemotherapy for diffuse large B-cell lymphoma …

Abstract The 2016 World Health Organization classification defines diffuse large B-cell
lymphoma (DLBCL) subtypes based on Epstein-Barr virus (EBV) infection and oncogenic …

Objectives Various studies have investigated the prognostic value of C-MYC aberrations in
diffuse large B-cell lymphoma (DLBCL). However, the role of C-MYC as an independent …

Background The survival of patients with diffuse large-B-cell lymphoma after chemotherapy
is influenced by molecular features of the tumors. We used the gene-expression profiles of …

Initial gene expression profiling studies of diffuse large B-cell lymphoma (DLBCL) revealed
that this single diagnosis actually encompasses two distinct diseases that differ in the …

Activated B-cell-like (ABC) diffuse large B-cell lymphoma (DLBCL), the major constituent of
nongerminal center B-cell-like (non-GCB) DLBCL, is associated with poorer survival …

Bcl-6 protein expression, a marker of germinal center origin, has been associated with a
favorable prognosis in diffuse large B-cell lymphoma (DLBCL). To determine the prognostic …